Pembrolizumab is an immune checkpoint inhibitor (ICI), an anti-PD-1 antibody, approved for the treatment of metastatic non-small-cell lung cancer (NSCLC). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.